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Abstract
Background: Few studies have investigated the factors affecting aerosol delivery during non-invasive ventilation
(NIV). Our aim was to investigate, using a bench-top model, the effect of different ventilator settings and positions
of the exhalation port and nebulizer on the amount of albuterol delivered to a lung simulator.
Methods: A lung model simulating spontaneous breathing was connected to a single-limb NIV ventilator, set in bi-
level positive airway pressure (BIPAP) with inspiratory/expiratory pressures of 10/5, 15/10, 15/5, and 20/10 cmH2O, or
continuous positive airway pressure (CPAP) of 5 and 10 cmH2O. Three delivery circuits were tested: a vented mask
with the nebulizer directly connected to the mask, and an unvented mask with a leak port placed before and after
the nebulizer. Albuterol was collected on a filter placed after the mask and then the delivered amount was
measured with infrared spectrophotometry.
Results: Albuterol delivery during NIV varied between 6.7 ± 0.4% to 37.0 ± 4.3% of the nominal dose. The amount
delivered in CPAP and BIPAP modes was similar (22.1 ± 10.1 vs. 24.0 ± 10.0%, p = 0.070). CPAP level did not affect delivery
(p = 0.056); in BIPAP with 15/5 cmH2O pressure the delivery was higher compared to 10/5 cmH2O (p = 0.033) and 20/10
cmH2O (p = 0.014). Leak port position had a major effect on delivery in both CPAP and BIPAP, the best performances
were obtained with the unvented mask, and the nebulizer placed between the leak port and the mask (p < 0.001).
Conclusions: In this model, albuterol delivery was marginally affected by ventilatory settings in NIV, while position of the
leak port had a major effect. Nebulizers should be placed between an unvented mask and the leak port in order to
maximize aerosol delivery.
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Background
Non-invasive positive pressure ventilation (NIV) is being
used increasingly in patients with either acute or chronic
respiratory failure [1]. The use of NIV as first line treat-
ment for acute exacerbations of chronic obstructive pul-
monary disease (COPD) have been confirmed by several
studies [2, 3] that showed a reduction of complications,
frequency of intubation and mortality in patients with
hypercapnic respiratory failure. Although cost-effectiveness
of long term NIV remains debated [4], in specific sub-
groups of COPD patients such as obese [5] or severely ill
patients [6], long term domiciliary home ventilator NIV
improves survival. In these patients, nebulized bronchodi-
lators are often used to relieve airway obstruction; however,
few studies have reported the factors affecting aerosol de-
livery during NIV and most of the studies focused on intu-
bated patients [7–9]. Previous studies showed that the
albuterol delivery, namely the amount that effectively
reaches the patients’ airways, is affected by the bi-level
positive airway pressure (BIPAP) ventilatory settings:
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respiratory rate, inspiratory positive airway pressure (IPAP)
and end expiratory positive airway pressure (EPAP) [10].
NIV can be delivered through several interfaces: the most
commonly used oro-nasal and nasal masks have a built-in
leak port, but this design resulted in reduced albuterol de-
livery in in-vitro studies [11, 12]. Conflicting results have
been reported concerning the role of the nebulizer and leak
port position with unvented masks [13, 14]. In a recent
study, CPAP administered with an high-flow system re-
sulted in low drug delivery rates; higher flows and lower
CPAP levels were associated with worse performances [15],
but these findings cannot be translated directly to patients
receiving CPAP through a NIV ventilator.
Our goal was to investigate, with a bench-top model, the
effect of different positions of the exhalation port and
nebulizer during CPAP or BIPAP administered with a dedi-
cated NIV ventilator on aerosol delivery. We tested masks
with and without built-in exhalation ports, using common
ventilator settings. We hypothesized that albuterol delivery
by nebulization during NIV is affected by the positions of
the exhalation port and pressure levels.
Methods
Experimental settings
A pneumatic lung simulator system (Dimar, Mirandola,
Italy) was set to mimic a patient with mild tachypnea with
a tidal volume of 400 mL, respiratory rate of 20 cycles per
minute, and inspiratory to expiratory ratio of 1:2. As illus-
trated in Fig. 1, the lung simulator was connected, through
a corrugated tube, to a rigid holed surface where the tested
masks were firmly fixed in order to avoid air leaks from the
mask seal. The masks were connected to a Puritan Bennett
560 non-invasive ventilator for domiciliary use (Covidien,
Dublin, Ireland), with a single-limb ventilatory circuit. The
ventilator was set in CPAP or BIPAP mode, in the latter
case with a rise time of 0.2 s and the inspiratory trigger sen-
sitivity set at −2 L/m.
The following commonly used ventilator settings were
tested: BIPAP mode, IPAP/EPAP of 10/5, 15/10, 15/5, and
20/10 cmH2O; CPAP with pressure levels of 5 and 10
cmH2O. Two oro-nasal masks were tested: a vented mask
incorporating a leak port (Respireo Primo F vented, Air
Liquide, France), and an unvented mask (Respireo Primo F
unvented, Air Liquide, France), with a single-arch leak port
(Respironics, Pennsylvania, US) in the ventilator circuit. For
a more detailed description of the respiratory circuits, see
Fig. 1. Nebulization was obtained with a small volume
nebulizer (Teleflex Hudson RCI, California, US), filled with
3 ml of distilled water containing 5 mg of albuterol, a clinic-
ally effective dose to relieve bronchospasm [16] and used in
previous bench studies [11], and driven with 8 L/m of oxy-
gen, according to the manufacturer’s recommendations.
The nebulizer was operated in the vertical position, for
10 min, time in which the nebulizer chamber was empty.
Each experimental condition was tested in three replicates.
Collection filter and albuterol detection
A custom-made collection filter, described in a previously
published study, was interposed between the mask and the




Fig. 1 Experimental settings, see text for detailed explanation. Configuration a: leak port included in the vented mask; Configuration b: leak port
between the nebulizer and the unvented mask; Configuration c: leak port between the nebulizer and the respiratory circuit
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simulator [15]. A commercially available ventilator circuit
filter (DAR Sterivent, Covidien, Dublin, Ireland) was
opened, its hydrophobic membrane removed and replaced
with 34 cm2 absorbent paper. At the end of each trial, the
filter was opened. Ten milliliters of distilled water were
used to wash the paper and the internal plastic surface of
the scaffold to extract albuterol. The solution was then
stirred for one minute with a vortex oscillator (ZX3, VELP
Scientifica, Monza, Italy). Each lavage solution was trans-
ferred to a 1 ml quartz cuvette, and its absorbance at
276 nm was measured with a spectrophotometer (Lambda
35, Perkin Elmer, Waltham, US). This method was adapted
from the current literature [13, 17, 18] and previously
described.
Statistical analysis
The amount of delivered albuterol was defined as per-
cent of the dose initially placed in the nebulizer that was
trapped by the collection filter, calculated with the fol-
lowing formula: (μg of albuterol detected/5,000 μg) ×
100. From a previous study [15], we expected an inter-
experimental standard deviation of 0.5%. Therefore, re-
peating each configuration test in three replicates would
have provided 80% power (1- β) to detect, with a two-
tailed α of 0.05, differences with an effect size of at least
2.8, corresponding to a 1.4% difference in albuterol de-
livery. The effect of CPAP, IPAP, EPAP and position of
the leak port on the percent of delivered albuterol were
assessed with a general linear model, with Sidak post-
hoc correction for multiple comparisons. The statistical
analysis was performed using SPSS version 21 (IBM,
Corp., Chicago, Illinois, US). Data were reported as
mean ± standard deviation, and statistical significance
was considered for p < 0.05.
Results
Albuterol delivery ranged between 6.7 ± 0.4 to 37.0 ±
4.3% of the nominal dose. Table 1 resumes the albuterol
delivery in all configurations. The average albuterol de-
livery in all BIPAP configurations did not differ from the
average delivery during CPAP (22.1 ± 10.1 vs. 24.0 ±
10.0%, respectively, p = 0.070).
In CPAP, pressure level marginally affected the amount
of delivered albuterol (p = 0.056), as illustrated in Fig. 2.
In BIPAP, the configuration with IPAP/EPAP of 15/5
cmH2O delivered higher albuterol amounts compared to
10/5 cmH2O (p = 0.033) and 20/10 cmH2O (p = 0.014),
as shown in Fig. 3.
In both CPAP and BIPAP, the most relevant differences
were observed changing the leak port position (p < 0.001 in
all pairwise comparisons), with the vented mask (Fig. 1a)
resulting in the lowest delivery, and the unvented mask with
the nebulizer placed between the mask and the leak port
(Fig. 1c) resulting in the highest delivery (Figs. 2 and 3).
Discussion
The main findings of this in-vitro study are: 1) the
amount of the delivered albuterol varied between 6.7
and 37% of the nominal dose and it was comparable in
CPAP and BIPAP mode; 3) the highest albuterol delivery
was obtained with the nebulizer placed between the leak
port and the non-vented mask; 4) there was no differ-
ence in albuterol delivery between the two tested CPAP
levels; 5) In BIPAP, ventilator settings marginally affected
albuterol delivery, with the best performances obtained
with 15/5 cmH2O IPAP/EPAP.
The use of NIV has gained popularity in the last de-
cades, becoming the first line therapy for patients pre-
senting with COPD, both during acute respiratory
failure and post discharge using dedicated ventilators
intended for domiciliary use [19]. Inhaled bronchodila-
tors are always part of the treatment during exacerbation
and long-term management of these patients. Although
there are a number of studies addressing inhaled drug
administration during invasive mechanical ventilation
[20–22], few data are available focusing on aerosol ther-
apy during application of NIV [12, 14]. Since home
BIPAP ventilators typically have a single limb respiratory
circuit, there are intrinsic differences with the two-limb
circuits used on intensive care ventilators. Therefore, the
Table 1 Albuterol delivery in each configuration
Airway Pressure (cmH2O) Albuterol delivery (% of dose)
Mode EPAP or CPAP IPAP Config. A Config. B Config. C Pairwise comparison
(between configurations)
CPAP 5 - 12.5 ± 0.4 26.4 ± 3.6 37.0 ± 4.3 p < 0.001
10 - 11.5 ± 1.7 23.9 ± 1.5 32.8 ± 2.6 p < 0.001
BIPAP 5 10 9.5 ± 1.0 22.1 ± 3.5 30.9 ± 1.5 p < 0.001
5 15 13.5 ± 3.6* 27.7 ± 1.9* 35.1 ± 4.0* p < 0.001
10 15 6.7 ± 0.4 25.2 ± 1.1 34.1 ± 3.6 p < 0.001
10 20 8.7 ± 0.9 25.7 ± 2.2 26.5 ± 6.1 p < 0.001
CPAP, Continuous Positive Airway Pressure, BIPAP Bilevel Positive Airway Pressure, EPAP Expiratory Positive Airway Pressure, IPAP Inspiratory Positive
Airway Pressure
*Significantly higher compared to BIPAP 10/5 cmH2O and BIPAP 20/10 cmH2O (p < 0.05)
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findings of studies using critical care ventilators cannot
be translated directly to this setting. The presence of an
intentional leak port in the circuit creates a bias flow to-
wards the exterior, potentially affecting drug delivery.
Our findings confirm what was previously described by
Chatmongkolchart et al., that reported an increased aerosol
delivery with the nebulizer placed between the mask and
the leak port during BIPAP [14]. A recent study by Dai et
al. [13] investigated the influence of different types of exhal-
ation valves and nebulizer positions, finding an opposite re-
sult for most of the tested configurations, reporting better
delivery when the nebulizer was placed between the NIV
ventilator and the leak port. Dai et al. studied different types
of exhalation valves, including the type used in our study.
With such single-arch valve, the role of nebulizer position
was puzzling and the best position varied at different venti-
lation settings. In our experimental setting the advantage of
configuration C was observed at all ventilator settings, con-
firming the findings of a previous study [14] and extending
it to CPAP ventilation.
During NIV, the exhalation port is incorporated within
the circuit or in the mask in order to allow gas washout
during exhalation. With a non-vented mask and the
nebulizer placed between the mask and the leak port, the
inspiratory pressure moves aerosol droplets to the patient.
During exhalation aerosol leaks from the exhalation port,
with a retrograde shift of aerosol droplets, potentially accu-
mulating in the tubing with the tubing acting as a reservoir
for delivery during the next inspiration. On the other hand,
when the nebulizer is located between the leak port and the
NIV ventilator, aerosol leakage occurs both in the inspira-
tory and early expiratory phases [14]. With a non-vented
mask and the nebulizer placed before the leak port, or with
the leak port incorporated in the mask, leakage occurs dur-
ing both inspiration and expiration causing a significant de-
crease of aerosol delivery.
In BIPAP mode, higher EPAP resulted in a slight de-
crease in bronchodilator delivery. Higher EPAP, causes a
higher retrograde flow during expiration with leakage of
aerosol through the leak port, as described previously
[14]. The IPAP/EPAP resulting in the highest aerosol de-
livery was 15/5 cmH2O. However, all ventilator pressure
settings only resulted in minor changes in the delivery
efficiency, especially when compared to the major effect
due to the position of the leak port.
This is the first study investigating albuterol delivery dur-
ing CPAP delivered with a single limb NIV ventilator. In a
recent study [15], aerosol delivery was studied during high-
flow Venturi-based CPAP administration: efficiency of aero-
sol delivery was affected by CPAP levels and driving flow,
and was low, with an average of 14% for the best perform-
ing respiratory circuit. The absolute value of drug delivery
in our study was comparable to those reported in the few
previous studies with BIPAP [13, 14], but higher than the
study investigating high-flow CPAP [15]: in our present
study, CPAP delivered through a NIV ventilator resulted in
higher delivery rates, above 30% at both 5 cmH2O and 10
cmH2O CPAP. This could be due to the fact that, in high
flow systems, flow itself is used to generate pressure result-
ing in a high bias flow through the CPAP valve, with a
washout effect on aerosol droplets. Differently, NIV ventila-
tors automatically adjust output flow to achieve the desired
pressures, therefore net flow from the respiratory circuit to
Fig. 2 Albuterol delivery during CPAP. See text for detailed description
of configurations A, B and C. *Pairwise comparisons between
configurations all p< 0.001
Fig. 3 Albuterol delivery during BIPAP. See text for detailed description of configurations A, B and C. *Pairwise comparisons between configurations
all p < 0.001
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the ambient is lower. On the other hand, this lack of a
significant circuit leak flow, along with the single-limb
circuit design, is what makes the presence of a leak port ne-
cessary. The position of the leak port in relationship to the
nebulizer was found to be the most determinant factor
influencing albuterol delivery, both in CPAP and BIPAP
modes.
Our experimental study has some limitations. We did
not investigate the effect of humidification, a known factor
affecting delivery [23]. We used two identical masks, dif-
fering only for the presence of an incorporated leak port.
Therefore, our results cannot be directly generalized to
other devices, including different types of interface, leak
ports and nebulizers using different mechanisms of action
[24]. Albuterol was nebulized continuously during both
inspiration and expiration: we would expect different re-
sults with nebulizers delivering aerosol only in the inspira-
tory phase. Moreover, only few commonly used pressure
levels were tested, in particular our study does not provide
information concerning higher inspiratory pressures, that
however are seldom used in the clinical practice. The find-
ings concerning leak port position and ventilator settings
should not be influenced by changes in these factors. Since
the clinical efficacy of aerosol inhalation depends on the
aerosol deposition in the airways, which is affected by the
ventilation mode, as well as the dead space and aerosol
particles penetration in the respiratory system, further
studies in-vivo are warranted to clarify these effects in
terms of clinical efficacy and side effects particularly in pa-
tients with type two respiratory failure.
Conclusions
In the present in-vitro model, the single factor most affect-
ing aerosol delivery during NIV or non-invasive CPAP de-
livered by a single circuit was the position of the nebulizer
and leak port. Drug delivery is greatest with the nebulizer
placed between the leak port and a non-vented mask, re-
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